Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

BACKGROUND: Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. PATIENTS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, M., Shimizu, S., Sato, T., Morimoto, M., Kojima, Y., Inaba, Y., Hagihara, A., Kudo, M., Nakamori, S., Kaneko, S., Sugimoto, R., Tahara, T., Ohmura, T., Yasui, K., Sato, K., Ishii, H., Furuse, J., Okusaka, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091321/
https://www.ncbi.nlm.nih.gov/pubmed/27573564
http://dx.doi.org/10.1093/annonc/mdw323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091321/
https://www.ncbi.nlm.nih.gov/pubmed/27573564
http://dx.doi.org/10.1093/annonc/mdw323

Ejemplares similares